# PDUFA dates November 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-11

> 522 FDA catalysts are dated in November 2025, including 6 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in November 2025?

PDUFA dates in November 2025: clemidsogene lanparvovec (RGNX) on November 9, 2025; REDEMPLO (plozasiran, ARWR) on November 18, 2025; KOMZIFTI (ziftomenib, KURA) on November 30, 2025; TEPKINLY (epcoritamab, GMAB) on November 30, 2025; YUVIWEL® (navepegritide, ASND) on November 30, 2025; KOMET-001 (KURA) on November 30, 2025. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-11)

Source: Press release filed with the SEC (EX-99), accession 0001193125-25-174947, https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2025-08-07. Cite: https://sec-api.dev/fda-calendar/2025-11#answer

## PDUFA dates in November 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| November 9, 2025 | REGENXBIO Inc. | RGNX | clemidsogene lanparvovec |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-ex99_1.htm) |
| November 18, 2025 | ARROWHEAD PHARMACEUTICALS, INC. | ARWR | REDEMPLO (plozasiran) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940725000007/a9912025-09x10arrowheadc.htm) |
| November 30, 2025 | Kura Oncology, Inc. | KURA | KOMZIFTI (ziftomenib) | relapsed or refractory NPM1-m AML | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-ex99_1.htm) |
| November 30, 2025 | GENMAB A/S | GMAB | TEPKINLY (epcoritamab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000061/gmab_20250807xex99d1.htm) |
| November 30, 2025 | Ascendis Pharma A/S | ASND | YUVIWEL® (navepegritide) | children with achondroplasia | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525277532/d88973dex991.htm) |
| November 30, 2025 | Kura Oncology, Inc. | KURA | KOMET-001 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/d939526dex991.htm) |

## All catalysts in November 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 2, 2025 | [Aria® (golimumab) complete response letter (CRL)](https://sec-api.dev/pdufa/golimumab) | ALVO |  | completed, complete response letter | "REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325006876/exh_991.htm)) |
| November 2, 2025 | [Buparlisib & paclitaxel primary completion](https://sec-api.dev/pdufa/buparlisib-and-paclitaxel) | ANL | Head and Neck Cancer | completed | "NCT04338399 (The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-02 (ACTUAL); Lead Sponsor Adlai Nortye Biopharma Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04338399)) |
| November 2, 2025 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | completed | "NCT05517421 (Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-02 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05517421)) |
| November 3, 2025 | [Sarepta Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed, missed | "For example, on November 3, 2025, we announced topline results from our ESSENCE trial, a confirmatory trial intended to verify the clinical benefits of VYONDYS 53 and AMONDYS 45, which primary endpoint did not meet statistical significance." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/873303/000119312526449721/srpt-20260930.htm)) |
| November 3, 2025 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/ex-991_q32025.htm)) |
| November 3, 2025 | [SGT-003 interim data readout](https://sec-api.dev/pdufa/sgt-003) | SLDB | Duchenne muscular dystrophy | completed, positive | "On November 3, 2025, the Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy at a dose level of 1E14vg/kg." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/d87050d8k.htm)) |
| November 3, 2025 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK | retina diseases, today | completed | "On November 3, 2025 we resubmitted the ONS-5010/LYTENAVA BLA and on December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm)) |
| November 3, 2025 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000119312525261689/pyxs-ex99_1.htm)) |
| November 3, 2025 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/ex_860184.htm)) |
| November 3, 2025 | [Karyopharm Therapeutics Inc. earnings report](https://sec-api.dev/companies/kpti/catalysts) | KPTI |  | completed | "Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1503802/000119312525261663/kpti-ex99_1.htm)) |
| November 3, 2025 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "SAN DIEGO, November 3, 2025 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter ended September 30, 2025 and provided an update on its recent corporate activities." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000044/ex991q320258-k.htm)) |
| November 3, 2025 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312525262591/srpt-ex99_1.htm)) |
| November 3, 2025 | [Solid Biosciences Inc. earnings report](https://sec-api.dev/companies/sldb/catalysts) | SLDB |  | completed | "Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/d87050dex991.htm)) |
| November 3, 2025 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., November 3, 2025 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm)) |
| November 3, 2025 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, November 3, 2025 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the third quarter ending September 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/a3q25exhibit991pr.htm)) |
| November 3, 2025 | [PRECISION BIOSCIENCES INC earnings report](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357874/000162828025047920/dtil-20251103xex991.htm)) |
| November 3, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm)) |
| November 3, 2025 | [ABVC BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/abvc/catalysts) | ABVC |  | completed | "(NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced its financial results for the quarter ended September 30, 2025, and provided an update on recent corporate developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/ea026348101ex99-1_abvcbio.htm)) |
| November 3, 2025 | [Ifezuntirgene inilparvovec NDA/BLA submission](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | completed | "In the final meeting minutes, and consistent with uniQure's November 3, 2025 press release, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission. uniQure is carefully evaluating the feedback and plans to urgently request a follow-up meeting with the FDA to take place in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465925118292/qure-20251204xex99d1.htm)) |
| November 3, 2025 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/sndx-ex99_1.htm)) |
| November 3, 2025 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "N.C., November 3, 2025 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925105199/tm2530004d1_ex99-1.htm)) |
| November 3, 2025 | [Xenon Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/xene/catalysts) | XENE |  | completed | "Xenon Reports Third Quarter 2025 Financial Results & Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000119312525262519/xene-ex99_1.htm)) |
| November 3, 2025 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/exh_991.htm)) |
| November 3, 2025 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525262576/d21938dex991.htm)) |
| November 3, 2025 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-ex99_1.htm)) |
| November 3, 2025 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Chronic Hepatitis B; Hepatitis B, Chronic | completed | "NCT05630820 (Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-03 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05630820)) |
| November 4, 2025 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/a3q25pressrelease.htm)) |
| November 4, 2025 | [Longeveron Inc. earnings report](https://sec-api.dev/companies/lgvn/catalysts) | LGVN |  | completed | "LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended September 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390025106117/ea026346001ex99-1_longeveron.htm)) |
| November 4, 2025 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm)) |
| November 4, 2025 | [Stoke Therapeutics, Inc. earnings report](https://sec-api.dev/companies/stok/catalysts) | STOK |  | completed | "Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1623526/000119312525264644/stok-ex99_1.htm)) |
| November 4, 2025 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/exhibit991-q0325.htm)) |
| November 4, 2025 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm)) |
| November 4, 2025 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000026/tmb-20251104xex99d1.htm)) |
| November 4, 2025 | [Biomea Fusion, Inc. earnings report](https://sec-api.dev/companies/bmea/catalysts) | BMEA |  | completed | "Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840439/000119312525264631/bmea-ex99_1.htm)) |
| November 4, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG Q3 2025 FINANCIAL RESULTS; RECENTLY RAISED 2025 REVENUE GUIDANCE TO" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104xex99d1.htm)) |
| November 4, 2025 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-ex99_1.htm)) |
| November 4, 2025 | [VOQUEZNA® (vonoprazan) trial start](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | completed | "On November 4, 2025, Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis ("EoE") in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/d20656d8k.htm)) |
| November 4, 2025 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312525263383/idya-ex99_1.htm)) |
| November 4, 2025 | [ANAPTYSBIO, INC earnings report](https://sec-api.dev/companies/anab/catalysts) | ANAB |  | completed | "Anaptys Announces Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000137005325000088/q32025earningsrelease.htm)) |
| November 4, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000104/spyre-20250930xexx991.htm)) |
| November 4, 2025 | [PHIBRO ANIMAL HEALTH CORP earnings report](https://sec-api.dev/companies/pahc/catalysts) | PAHC |  | completed | "Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069899/000110465925107064/pahc-20251104xex99d1.htm)) |
| November 4, 2025 | [PFIZER INC label expansion decision](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed, approved | "Pfizer and BioNTech announced the FDA approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/pfe-09282025xex99.htm)) |
| November 4, 2025 | [Lifevantage Corp earnings report](https://sec-api.dev/companies/lfvn/catalysts) | LFVN |  | completed | "LifeVantage Announces Financial Results for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/849146/000162828025048801/earningsrelease_q1fy26.htm)) |
| November 4, 2025 | [VAX-24 earnings report](https://sec-api.dev/pdufa/vax-24) | PCVX |  | completed | "Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx20251104-exx991.htm)) |
| November 4, 2025 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/hrtx-ex99_1.htm)) |
| November 4, 2025 | [Zomedica Corp. earnings report](https://sec-api.dev/companies/zomdf/catalysts) | ZOMDF |  | completed | "Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684144/000165495425012575/zom_ex991.htm)) |
| November 4, 2025 | [Nuvectis Pharma, Inc. earnings report](https://sec-api.dev/companies/nvct/catalysts) | NVCT |  | completed | "Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1875558/000110465925105953/tm2530070d1_ex99-1.htm)) |
| November 4, 2025 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000162828025048850/a2025q3ex991.htm)) |
| November 4, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "ImmunityBio Reports Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm)) |
| November 4, 2025 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/pfe-09282025xex99.htm)) |
| November 4, 2025 | [Verastem, Inc. earnings report](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | completed | "BOSTON--(BUSINESS WIRE)—Nov. 4, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm)) |
| November 4, 2025 | [Werewolf Therapeutics, Inc. earnings report](https://sec-api.dev/companies/howl/catalysts) | HOWL |  | completed | "Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785530/000178553025000030/a09302025ex991.htm)) |
| November 4, 2025 | [Relay Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rlay/catalysts) | RLAY |  | completed | "Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1812364/000119312525269536/rlay-ex99_1.htm)) |
| November 4, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm)) |
| November 4, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel20250930exhibit991.htm)) |
| November 4, 2025 | [Cryoport, Inc. earnings report](https://sec-api.dev/companies/cyrx/catalysts) | CYRX |  | completed | "Tennessee, November 4, 2025, - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124524/000110465925106421/tm2530148d1_ex99-1.htm)) |
| November 4, 2025 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "(NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the third quarter ended September 30, 2025 and provided recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_ex99-1.htm)) |
| November 4, 2025 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/exh_991.htm)) |
| November 4, 2025 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)) |
| November 4, 2025 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/kymr-ex99_1.htm)) |
| November 4, 2025 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/mirm-20251104xexx991.htm)) |
| November 4, 2025 | [VAX-24 interim data readout](https://sec-api.dev/pdufa/vax-24) | PCVX |  | completed, positive | "Today, the Company shared the final safety, tolerability, and immunogenicity results from this study that are consistent with the previously reported positive interim data and show that VAX-24 elicited robust, dose-dependent immune responses, with little to no evidence of carrier suppression observed." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx20251104-exx991.htm)) |
| November 4, 2025 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/exhibit991tarsus1142025pre.htm)) |
| November 4, 2025 | [Taysha Gene Therapies, Inc. earnings report](https://sec-api.dev/companies/tsha/catalysts) | TSHA |  | completed | "Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525263543/d17004dex991.htm)) |
| November 4, 2025 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062025000108/exhibit991_q32025earningsr.htm)) |
| November 4, 2025 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000110465925106282/tm2530133d1_ex99-1.htm)) |
| November 4, 2025 | [Beam Therapeutics Inc. earnings report](https://sec-api.dev/companies/beam/catalysts) | BEAM |  | completed | "Beam Therapeutics Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745999/000119312525263536/beam-ex99_1.htm)) |
| November 4, 2025 | [STANDARD BIOTOOLS INC. earnings report](https://sec-api.dev/companies/lab/catalysts) | LAB |  | completed | "Standard BioTools Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1162194/000119312525264693/lab-ex99_1.htm)) |
| November 4, 2025 | [Zoetis Inc. earnings report](https://sec-api.dev/companies/zts/catalysts) | ZTS |  | completed | "Zoetis Announces Third Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1555280/000155528025000272/exhibit99q32025.htm)) |
| November 4, 2025 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312525263684/tngx-ex99_1.htm)) |
| November 4, 2025 | [LINZESS® (linaclotide) label expansion decision](https://sec-api.dev/pdufa/linaclotide) | ABBV |  | completed, approved | "NDA202811 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20251104, review_priority PRIORITY; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22)) |
| November 4, 2025 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia | completed | "NCT04008706 (Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04008706)) |
| November 4, 2025 | [Kesimpta (ofatumumab) primary completion](https://sec-api.dev/pdufa/ofatumumab) | NVS | Multiple Sclerosis | completed | "NCT04788615 (Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04788615)) |
| November 4, 2025 | [MRNA-1647 primary completion](https://sec-api.dev/pdufa/mrna-1647) | MRNA | Cytomegalovirus Infection | withdrawn | "NCT05085366 (A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05085366)) |
| November 4, 2025 | [Toothpaste containing 8% arginine primary completion](https://sec-api.dev/pdufa/toothpaste-containing-8-arginine) | CL | Hypersensitivity | completed | "NCT07257042 (Oothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal Hypersensitivity): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07257042)) |
| November 4, 2025 | [Nda210862 complete response letter (CRL)](https://sec-api.dev/pdufa/nda210862) | BHVN |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 11/04/2025 for NDA 210862 to Biohaven Therapeutics, Ltd.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA210862_20251104.pdf%22)) |
| November 5, 2025 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Larimar Therapeutics Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/lrmr-ex99_1.htm)) |
| November 5, 2025 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm)) |
| November 5, 2025 | [X4 Pharmaceuticals, Inc earnings report](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed | "X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm)) |
| November 5, 2025 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465925107008/nxtc-20251105xex99d1.htm)) |
| November 5, 2025 | [Sonelokimab earnings report](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | completed | "MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/moonlake-pressreleasexq320.htm)) |
| November 5, 2025 | [Revolution Medicines, Inc. earnings report](https://sec-api.dev/companies/rvmd/catalysts) | RVMD |  | completed | "Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000119312525266836/rvmd-ex99_1.htm)) |
| November 5, 2025 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/a3q25financialpr.htm)) |
| November 5, 2025 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "Tempest Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/tpst-ex99_1.htm)) |
| November 5, 2025 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "BRISBANE, Calif., November 5, 2025 - Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312525265799/vera-ex99_1.htm)) |
| November 5, 2025 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000027/q32025-ex991earningsrelease.htm)) |
| November 5, 2025 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125040539/ef20058354_ex99-1.htm)) |
| November 5, 2025 | [Elanco Animal Health Inc earnings report](https://sec-api.dev/companies/elan/catalysts) | ELAN |  | completed | "Elanco Animal Health Reports Third Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739104/000173910425000068/elanco-20250930exhibit991.htm)) |
| November 5, 2025 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "CYTOKINETICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm)) |
| November 5, 2025 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "Zevra Reports Third Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000143464725000009/zvra-20251105xex991.htm)) |
| November 5, 2025 | [Compass Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cmpx/catalysts) | CMPX |  | completed | "Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325007004/exh_991.htm)) |
| November 5, 2025 | [PERRIGO Co plc earnings report](https://sec-api.dev/companies/prgo/catalysts) | PRGO |  | completed | "Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585364/000158536425000153/cy25q3ex991pressrelease.htm)) |
| November 5, 2025 | [Sionna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sion/catalysts) | SION |  | completed | "Sionna Therapeutics Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000162828025049246/sion3q25earningsrelease_fi.htm)) |
| November 5, 2025 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2025 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_ex99-1.htm)) |
| November 5, 2025 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312525266979/dyn-ex99_1.htm)) |
| November 5, 2025 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/goss-20251105xexx991.htm)) |
| November 5, 2025 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/a991q325pressrelease.htm)) |
| November 5, 2025 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achievements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925107014/tm2530226d1_ex99-1.htm)) |
| November 5, 2025 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/tyra-ex99_1.htm)) |
| November 5, 2025 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm)) |
| November 5, 2025 | [VEPPANU (vepdegestrant) NDA/BLA acceptance](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | estrogen receptor 1 | completed | "•Announced the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for vepdegestrant for the treatment of estrogen receptor 1 (ESR1) mutated, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer previously treated with endocrine-based therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/q32025earningsrelease.htm)) |
| November 5, 2025 | [Upstream Bio, Inc. earnings report](https://sec-api.dev/companies/upb/catalysts) | UPB |  | completed | "Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000119312525265705/upb-ex99_1.htm)) |
| November 5, 2025 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/exh_991.htm)) |
| November 5, 2025 | [Keros Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kros/catalysts) | KROS |  | completed | "Keros Therapeutics Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1664710/000166471025000086/exhibit991q32025.htm)) |
| November 5, 2025 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/sdgr-20250930xexx991.htm)) |
| November 5, 2025 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000110465925110375/mxct-20251112xex99d1.htm)) |
| November 5, 2025 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "ROYALTY PHARMA REPORTS THIRD QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276825000113/rprx-20250930rpplcpressxre.htm)) |
| November 5, 2025 | [Vir Biotechnology, Inc. earnings report](https://sec-api.dev/companies/vir/catalysts) | VIR |  | completed | "Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1706431/000162828025049561/a20251105-q3ex991earningsr.htm)) |
| November 5, 2025 | [Adaptive Biotechnologies Corp earnings report](https://sec-api.dev/companies/adpt/catalysts) | ADPT |  | completed | "Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000119312525266974/adpt-ex99_1.htm)) |
| November 5, 2025 | [IMM-529 FDA approval](https://sec-api.dev/pdufa/imm-529) | IMRN |  | completed, approved | "2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that the United States Food and Drug Administration (FDA) has approved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660046/000121390025106425/ea026414101ex99-1_immuron.htm)) |
| November 5, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000162828025049564/q32025eolsex991.htm)) |
| November 5, 2025 | [CHARLES RIVER LABORATORIES INTERNATIONAL, INC. earnings report](https://sec-api.dev/companies/crl/catalysts) | CRL |  | completed | "WILMINGTON, MA, November 5, 2025 - Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1100682/000110068225000041/crl3q25earningsrelease.htm)) |
| November 5, 2025 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/lxeo-ex99_1.htm)) |
| November 5, 2025 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/gern-20250930xexx991.htm)) |
| November 5, 2025 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312525266959/acad-ex99_1.htm)) |
| November 5, 2025 | [Xencor Inc earnings report](https://sec-api.dev/companies/xncr/catalysts) | XNCR |  | completed | "Xencor Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673225000086/xncr-20251105xexx991.htm)) |
| November 5, 2025 | [Boundless Bio, Inc. earnings report](https://sec-api.dev/companies/bold/catalysts) | BOLD |  | completed | "SAN DIEGO, November 5, 2025 - Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782303/000119312525265707/bold-ex99_1.htm)) |
| November 5, 2025 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "November 5, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter of 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-ex99_1.htm)) |
| November 5, 2025 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/d33707dex991.htm)) |
| November 5, 2025 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525265708/d27174dex991.htm)) |
| November 5, 2025 | [DT-818 earnings report](https://sec-api.dev/pdufa/dt-818) | DSGN |  | completed | "Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312525266933/dsgn-ex99_1.htm)) |
| November 5, 2025 | [Dianthus Therapeutics, Inc. /DE/ earnings report](https://sec-api.dev/companies/dnth/catalysts) | DNTH |  | completed | "AND REPORTS Q3 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525266867/dnth-ex99_1.htm)) |
| November 5, 2025 | [Adicet Bio, Inc. earnings report](https://sec-api.dev/companies/acet/catalysts) | ACET |  | completed | "Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720580/000119312525266860/acet-ex99_1.htm)) |
| November 5, 2025 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/q32025earningsrelease.htm)) |
| November 5, 2025 | [Caplyta (lumateperone tosylate) label expansion decision](https://sec-api.dev/pdufa/lumateperone) | JNJ |  | completed, approved | "NDA209500 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20251105, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22)) |
| November 5, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Bladder Cancer | withdrawn | "NCT02625961 (Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-11-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-11-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02625961)) |
| November 5, 2025 | [Ingrezza Sprinkle (valbenazine tosylate) primary completion](https://sec-api.dev/pdufa/valbenazine) | NBIX | Chorea, Huntington | withdrawn | "NCT04400331 (Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-05 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04400331)) |
| November 6, 2025 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2025 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/tm2529979d1_ex99-1.htm)) |
| November 6, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/d81968dex991.htm)) |
| November 6, 2025 | [Aligos Therapeutics, Inc. earnings report](https://sec-api.dev/companies/algs/catalysts) | ALGS |  | completed | "Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1799448/000117184325007075/exh_991.htm)) |
| November 6, 2025 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465925107390/tm2530237d1_ex99-1.htm)) |
| November 6, 2025 | [Alector, Inc. earnings report](https://sec-api.dev/companies/alec/catalysts) | ALEC |  | completed | "Alector Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1653087/000119312525269537/alec-ex99_1.htm)) |
| November 6, 2025 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/ex_854696.htm)) |
| November 6, 2025 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/q32025earningsrelease_ex991.htm)) |
| November 6, 2025 | [Ginkgo Bioworks Holdings, Inc. earnings report](https://sec-api.dev/companies/dna/catalysts) | DNA |  | completed | "Ginkgo Bioworks Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830214/000183021425000013/ex991earningspr.htm)) |
| November 6, 2025 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828025049821/exhibit991-q32025earningsr.htm)) |
| November 6, 2025 | [COLLEGIUM PHARMACEUTICAL, INC earnings report](https://sec-api.dev/companies/coll/catalysts) | COLL |  | completed | "Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1267565/000110465925107389/coll-20251106xex99d1.htm)) |
| November 6, 2025 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/pressrelease-q32025.htm)) |
| November 6, 2025 | [PROTHENA CORP PUBLIC LTD CO earnings report](https://sec-api.dev/companies/prta/catalysts) | PRTA |  | completed | "Prothena Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1559053/000155905325000042/exhibit991q32025earningsre.htm)) |
| November 6, 2025 | [Replimune Group, Inc. earnings report](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "2025 - Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_ex99-1.htm)) |
| November 6, 2025 | [Neurogene trial start](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000091/ngne_prxdosedfirstparticip.htm)) |
| November 6, 2025 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/ex_858472.htm)) |
| November 6, 2025 | [Lipocine Inc. earnings report](https://sec-api.dev/companies/lpcn/catalysts) | LPCN |  | completed | "Announces Financial Results for the Third quarter Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1535955/000149315225021008/ex99-1.htm)) |
| November 6, 2025 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm)) |
| November 6, 2025 | [MARAVAI LIFESCIENCES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/mrvi/catalysts) | MRVI |  | completed | "MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1823239/000182323925000117/exhibit991-q32025.htm)) |
| November 6, 2025 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000119312525269534/lctx-ex99_1.htm)) |
| November 6, 2025 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106xex99d1.htm)) |
| November 6, 2025 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000056/sttk_3q2025earningsrelease.htm)) |
| November 6, 2025 | [Viatris Inc FDA approval](https://sec-api.dev/companies/vtrs/catalysts) | VTRS | iron deficiency anemia in adult and pediatric patients | completed, approved | "•Iron Sucrose Injection: The Company announced that the FDA approved its Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients (2 years of age and older) with chronic kidney disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/exhibit991-3q25earningsrel.htm)) |
| November 6, 2025 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/iron-ex99_1.htm)) |
| November 6, 2025 | [Sana Biotechnology, Inc. earnings report](https://sec-api.dev/companies/sana/catalysts) | SANA |  | completed | "Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770121/000119312525269522/sana-ex99_1.htm)) |
| November 6, 2025 | [Camp4 Therapeutics Corp earnings report](https://sec-api.dev/companies/camp/catalysts) | CAMP |  | completed | "CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736730/000173673025000092/exhibit991-camp4reportsthi.htm)) |
| November 6, 2025 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148925000058/vtvt-20250930xexx991pressr.htm)) |
| November 6, 2025 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/exhibit991-3q25earningsrel.htm)) |
| November 6, 2025 | [Rallybio Corp earnings report](https://sec-api.dev/companies/rlyb/catalysts) | RLYB |  | completed | "Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-2025116xex991pressrel.htm)) |
| November 6, 2025 | [Prestige Consumer Healthcare Inc. earnings report](https://sec-api.dev/companies/pbh/catalysts) | PBH |  | completed | "TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 6, 2025-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1295947/000129594725000037/exhibit991fy26-q2earningsr.htm)) |
| November 6, 2025 | [Dogwood Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dwtx/catalysts) | DWTX |  | completed | "ATLANTA, Ga., November 6, 2025 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818844/000110465925107471/dwtx-20251106xex99d1.htm)) |
| November 6, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports third quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125040664/ef20058378_ex99-1.htm)) |
| November 6, 2025 | [Syndrome trial start](https://sec-api.dev/pdufa/syndrome) | NGNE | Rett syndrome | completed | "NEW YORK - November 6, 2025 - Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden™ registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000091/ngne_prxdosedfirstparticip.htm)) |
| November 6, 2025 | [PLIANT THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/plrx/catalysts) | PLRX |  | completed | "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746473/000174647325000173/plrx-20251106xexx991.htm)) |
| November 6, 2025 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000192/ex991pressreleaseq32025.htm)) |
| November 6, 2025 | [C4 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cccc/catalysts) | CCCC |  | completed | "C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662579/000162828025049850/cccc-20251106xexx991.htm)) |
| November 6, 2025 | [ZUSDURI (mitomycin) earnings report](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925033466/ex_880398.htm)) |
| November 6, 2025 | [Zymeworks Inc. earnings report](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765325000076/ex991q32025_earningsxrelea.htm)) |
| November 6, 2025 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/stro-ex99_1.htm)) |
| November 6, 2025 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000119312525269442/inab-ex99_1.htm)) |
| November 6, 2025 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/ex991earningsrelease3q25.htm)) |
| November 6, 2025 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000048/nvax3q25earningspressrelea.htm)) |
| November 6, 2025 | [Black Diamond Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bdtx/catalysts) | BDTX |  | completed | "Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701541/000170154125000038/bdtx-exhibit991_q32025.htm)) |
| November 6, 2025 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "or "the Company") today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925107753/tm2530353d1_ex99-1.htm)) |
| November 6, 2025 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| November 6, 2025 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "Aptevo Therapeutics Reports 3Q25 Financial Results And" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000119312525269470/apvo-ex99_1.htm)) |
| November 6, 2025 | [Entrada Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trda/catalysts) | TRDA |  | completed | "Entrada Therapeutics Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689375/000168937525000049/entradatherapeuticsreports.htm)) |
| November 6, 2025 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390025107180/ea026426101ex99-1_nektar.htm)) |
| November 6, 2025 | [OnKure Therapeutics, Inc. earnings report](https://sec-api.dev/companies/okur/catalysts) | OKUR |  | completed | "OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1637715/000119312525269468/okur-ex99_1.htm)) |
| November 6, 2025 | [SANGAMO THERAPEUTICS, INC earnings report](https://sec-api.dev/companies/sgmoq/catalysts) | SGMOQ |  | completed | "RICHMOND, California, November 6, 2025 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and third quarter 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001233/000100123325000023/exhibit-991110625.htm)) |
| November 6, 2025 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/acrs-20251106xex99d1.htm)) |
| November 6, 2025 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/glue-ex99_1.htm)) |
| November 6, 2025 | [Tectonic Therapeutic, Inc. earnings report](https://sec-api.dev/companies/tecx/catalysts) | TECX |  | completed | "Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000119312525269573/tecx-ex99_1.htm)) |
| November 6, 2025 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/maze-ex99_1.htm)) |
| November 6, 2025 | [Cardiff Oncology, Inc. earnings report](https://sec-api.dev/companies/crdf/catalysts) | CRDF |  | completed | "Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213037/000119312525269492/crdf-ex99_1.htm)) |
| November 6, 2025 | [CytomX Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctmx/catalysts) | CTMX |  | completed | "CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501989/000119312525269533/ctmx-ex99_1.htm)) |
| November 6, 2025 | [Quoin Pharmaceuticals Ltd. earnings report](https://sec-api.dev/companies/qnrx/catalysts) | QNRX |  | completed | "Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate update today and announced its financial results for the third quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465925107747/tm2530187d1_ex99-1.htm)) |
| November 6, 2025 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036125040775/ef20058429_ex99-1.htm)) |
| November 6, 2025 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312525268134/whwk-ex99_1.htm)) |
| November 6, 2025 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312525269518/janx-ex99_1.htm)) |
| November 6, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828025049880/ex991earningsreleaseq32025.htm)) |
| November 6, 2025 | [BioAge Labs, Inc. earnings report](https://sec-api.dev/companies/bioa/catalysts) | BIOA |  | completed | "BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709941/000119312525269986/bioa-ex99_1.htm)) |
| November 6, 2025 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429225000023/zlab-2025116x8kex991.htm)) |
| November 6, 2025 | [ATYR PHARMA INC earnings report](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed | "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000119312525269486/atyr-ex99_1.htm)) |
| November 6, 2025 | [AbCellera Biologics Inc. earnings report](https://sec-api.dev/companies/abcl/catalysts) | ABCL |  | completed | "VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703057/000170305725000024/q32025earningspressrelease.htm)) |
| November 6, 2025 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000119312525269654/orgo-ex99_1.htm)) |
| November 6, 2025 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/cgem-ex99_1.htm)) |
| November 6, 2025 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036125040774/ef20058531_ex99-1.htm)) |
| November 6, 2025 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312525269722/rani-ex99_1.htm)) |
| November 6, 2025 | [LB PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lbrx/catalysts) | LBRX |  | completed | "LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1691082/000119312525268154/d84790dex991.htm)) |
| November 6, 2025 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/exhibit9912025q3pressrelea.htm)) |
| November 6, 2025 | [Avalo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/avtx/catalysts) | AVTX |  | completed | "Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000153412025000017/ex-9913q2025earningsrelease.htm)) |
| November 6, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Third Quarter 2025 Financial Results;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828025050145/pcrx-09302025x991.htm)) |
| November 6, 2025 | [REVELATION BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/revb/catalysts) | REVB |  | completed | "Revelation Biosciences, Inc. Announces Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076833/revb-ex99_1.htm)) |
| November 6, 2025 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000119312525268075/clym-ex99_1.htm)) |
| November 6, 2025 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000104/ints20251106ex99120250930p.htm)) |
| November 6, 2025 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "-- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter and year-to-date 2025 financial results, business achievements, pipeline progress, and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465925107426/tm2530236d1_ex99-1.htm)) |
| November 6, 2025 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "- Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the three months ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925107743/tm2529989d1_ex99-1.htm)) |
| November 6, 2025 | [Altimmune, Inc. earnings report](https://sec-api.dev/companies/alt/catalysts) | ALT |  | completed | "Altimmune Announces Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/alt-20251106xex99d1.htm)) |
| November 6, 2025 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20251106, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| November 6, 2025 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718425000062/amph-20251106xex99d1.htm)) |
| November 6, 2025 | [Emavusertib earnings report](https://sec-api.dev/pdufa/emavusertib) | CRIS |  | completed | "LEXINGTON, Mass., November 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000105/a3q25earningspressrelease.htm)) |
| November 6, 2025 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/imnm-ex99_1.htm)) |
| November 6, 2025 | [NATURES SUNSHINE PRODUCTS INC earnings report](https://sec-api.dev/companies/natr/catalysts) | NATR |  | completed | "Nature's Sunshine Reports Strong Third Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/275053/000162828025050268/natrq32025earningsrelease.htm)) |
| November 6, 2025 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465925107447/mtva-20251106xex99d1.htm)) |
| November 6, 2025 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000156604425000007/vyne-2025116q32025exx991.htm)) |
| November 6, 2025 | [Rapport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rapp/catalysts) | RAPP |  | completed | "BOSTON and SAN DIEGO, November 6, 2025 -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the third quarter ending September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000119312525268072/rapp-ex99_1.htm)) |
| November 6, 2025 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "CHICAGO, IL (BUSINESS WIRE); November 6, 2025 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000156/exh991q32025earningsrelease.htm)) |
| November 6, 2025 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/amlx-ex99_1.htm)) |
| November 6, 2025 | [Allogene Therapeutics, Inc. earnings report](https://sec-api.dev/companies/allo/catalysts) | ALLO |  | completed | "Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737287/000162828025050227/allo-20250930xexx991q325.htm)) |
| November 6, 2025 | [Cartesian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rnac/catalysts) | RNAC |  | completed | "Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/exhibit991_earningsrelease.htm)) |
| November 6, 2025 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, November 6, 2025 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2025, and provided an update on key corporate milestones and accomplishments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282225000049/pressreleaseearningsq311-0.htm)) |
| November 6, 2025 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/tm2530323d1_ex99-1.htm)) |
| November 6, 2025 | [Neumora Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nmra/catalysts) | NMRA |  | completed | "Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-ex99_1.htm)) |
| November 6, 2025 | [LIFECORE BIOMEDICAL, INC. \DE\ earnings report](https://sec-api.dev/companies/lfcr/catalysts) | LFCR |  | completed | "Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/lfcr-ty25q3xex991earningsr.htm)) |
| November 6, 2025 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/sln-ex99_1.htm)) |
| November 6, 2025 | [Viaskintm peanut primary completion](https://sec-api.dev/pdufa/viaskintm-peanut) | DBVT | Allergy, Peanut | completed | "NCT05741476 (Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-06 (ACTUAL); Lead Sponsor DBV Technologies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05741476)) |
| November 7, 2025 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000107/anip-20251107xexx991.htm)) |
| November 7, 2025 | [Surrozen, Inc./DE earnings report](https://sec-api.dev/companies/srzn/catalysts) | SRZN |  | completed | "Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824893/000119312525272363/srzn-ex99_1.htm)) |
| November 7, 2025 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports Third Quarter Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000119312525277556/krro-ex99_1.htm)) |
| November 7, 2025 | [KIORA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/kprx/catalysts) | KPRX |  | completed | "Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251425000079/ex991-pressreleaseseptembe.htm)) |
| November 7, 2025 | [ALX ONCOLOGY HOLDINGS INC earnings report](https://sec-api.dev/companies/alxo/catalysts) | ALXO |  | completed | "ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810182/000119312525271112/alxo-ex99_1.htm)) |
| November 7, 2025 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/gyre-ex99_1.htm)) |
| November 7, 2025 | [Prime Medicine, Inc. earnings report](https://sec-api.dev/companies/prme/catalysts) | PRME |  | completed | "Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1894562/000162828025050415/q320258-kex991xpressrelease.htm)) |
| November 7, 2025 | [EXICURE, INC. earnings report](https://sec-api.dev/companies/xcur/catalysts) | XCUR |  | completed | "Exicure, Inc. Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1698530/000169853025000099/a8kq32025exhibit991.htm)) |
| November 7, 2025 | [PTR (ptr) NDA/BLA acceptance](https://sec-api.dev/pdufa/ptr) | CING |  | completed | "CITY, Kan., Nov.10, 2025 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (NDA) for CTx-1301 (dexmethylphenidate HCl) and assignment of a Prescription" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315225021410/ex99-1.htm)) |
| November 7, 2025 | [Brexafemme (ibrexafungerp) primary completion](https://sec-api.dev/pdufa/ibrexafungerp) | SCYX | Candidiasis, Invasive; Candidemia | withdrawn | "NCT05178862 (A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-07 (ACTUAL); Lead Sponsor Scynexis, Inc.; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05178862)) |
| November 7, 2025 | [Inclacumab primary completion](https://sec-api.dev/pdufa/inclacumab) | PFE |  | withdrawn | "NCT05348915 (A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-07 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05348915)) |
| November 7, 2025 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Major Depressive Disorder | completed | "NCT06419608 (Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-07 (ACTUAL); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06419608)) |
| November 9, 2025 | [Clemidsogene lanparvovec PDUFA date](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | delayed | "In May 2025, the U.S. Food and Drug Administration (FDA) granted priority review of the BLA seeking accelerated approval for clemidsogene lanparvovec for MPS II; Prescription Drug User Fee Act (PDUFA) target action date of November 9, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-ex99_1.htm)) |
| November 10, 2025 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828025050796/adct-20250930pressrelease.htm)) |
| November 10, 2025 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925108806/tm2530577d1_ex99-1.htm)) |
| November 10, 2025 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys2025q38kex991.htm)) |
| November 10, 2025 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000045/q32025pr1.htm)) |
| November 10, 2025 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | "Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000119312525273373/sepn-ex99_1.htm)) |
| November 10, 2025 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE - November 10, 2025 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000119312525274318/catx-ex99_1.htm)) |
| November 10, 2025 | [Cadrenal Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cvkd/catalysts) | CVKD |  | completed | "Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937993/000121390025107949/ea026472401ex99-1_cadrenal.htm)) |
| November 10, 2025 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000064/ino-93025x8kex991.htm)) |
| November 10, 2025 | [Roivant Sciences Ltd. earnings report](https://sec-api.dev/companies/roiv/catalysts) | ROIV |  | completed | "Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1635088/000114036125041269/ef20058314_ex99-1.htm)) |
| November 10, 2025 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated commercial biotechnology company today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent operational highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125017369/ex99-01.htm)) |
| November 10, 2025 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/exhibit99120251110.htm)) |
| November 10, 2025 | [Cabaletta Bio, Inc. earnings report](https://sec-api.dev/companies/caba/catalysts) | CABA |  | completed | "Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759138/000119312525273272/caba-ex99_1.htm)) |
| November 10, 2025 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525001555/e664953_ex99-1.htm)) |
| November 10, 2025 | [CRISPR Therapeutics AG earnings report](https://sec-api.dev/companies/crsp/catalysts) | CRSP |  | completed | "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/crsp-ex99_1.htm)) |
| November 10, 2025 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000202365825000107/pressreleaseq32025.htm)) |
| November 10, 2025 | [Editas Medicine, Inc. earnings report](https://sec-api.dev/companies/edit/catalysts) | EDIT |  | completed | "Editas Medicine Announces Third Quarter 2025 Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650664/000165066425000153/editasmedicinepressrelease.htm)) |
| November 10, 2025 | [ASSEMBLY BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/asmb/catalysts) | ASMB |  | completed | "Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1426800/000119312525274235/asmb-ex99_1.htm)) |
| November 10, 2025 | [Jasper Therapeutics, Inc. earnings report](https://sec-api.dev/companies/jspr/catalysts) | JSPR |  | completed | "Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm)) |
| November 10, 2025 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/ex_885764.htm)) |
| November 10, 2025 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465925108802/qure-20251110xex99d1.htm)) |
| November 10, 2025 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000119312525274220/annx-ex99_1.htm)) |
| November 10, 2025 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/a2025q3bhvnearningsprex991.htm)) |
| November 10, 2025 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the Third Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/tm2530711d1_ex99-1.htm)) |
| November 10, 2025 | [4D Molecular Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fdmt/catalysts) | FDMT |  | completed | "4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525273340/fdmt-ex99_1.htm)) |
| November 10, 2025 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "LEXINGTON, Mass. — November 10, 2025 — Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312525273266/agen-ex99_1.htm)) |
| November 10, 2025 | [Tenaya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tnya/catalysts) | TNYA |  | completed | "Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858848/000119312525273230/tnya-ex99_1.htm)) |
| November 10, 2025 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-ex99_1.htm)) |
| November 10, 2025 | [Mereo BioPharma Group plc earnings report](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed | "Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719714/000119312525274319/mreo-ex99_1.htm)) |
| November 10, 2025 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312525273278/d44041dex991.htm)) |
| November 10, 2025 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics, Inc. (Nasdaq: TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm)) |
| November 10, 2025 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312525273107/spry-ex99_1.htm)) |
| November 10, 2025 | [INTEGRATED BIOPHARMA INC earnings report](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | completed | "HILLSIDE, NEW JERSEY (November 10, 2025) - Integrated BioPharma, Inc. (OTCQX: INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1016504/000143774925034091/ex_885177.htm)) |
| November 10, 2025 | [CTX611 trial start](https://sec-api.dev/pdufa/srsd107) | CRSP |  | completed | "In September, CRISPR Therapeutics and its partner Sirius Therapeutics announced that the first patient was dosed in Europe in the Phase 2 clinical trial of SRSD107, a long-acting Factor XI (FXI) small interfering RNA (siRNA) for thromboembolic disorders." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/crsp-ex99_1.htm)) |
| November 10, 2025 | [Passage BIO, Inc. earnings report](https://sec-api.dev/companies/pasg/catalysts) | PASG |  | completed | "PASSAGE BIO REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787297/000110465925109158/pasg-20251110xex99d1.htm)) |
| November 10, 2025 | [Nkarta, Inc. earnings report](https://sec-api.dev/companies/nktx/catalysts) | NKTX |  | completed | "Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000119312525274261/nktx-ex99_1.htm)) |
| November 10, 2025 | [Skye Bioscience, Inc. earnings report](https://sec-api.dev/companies/skye/catalysts) | SKYE |  | completed | "SAN DIEGO, CA, November 10, 2025 -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company"), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the third quarter ended September 30, 2025, along with key accomplishments and upcoming milestones." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000162828025051035/skye-20250930xfinancialres.htm)) |
| November 10, 2025 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/pvla-ex99_1.htm)) |
| November 10, 2025 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000119312525274216/sprb-ex99_1.htm)) |
| November 10, 2025 | [Zentalis Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/zntl/catalysts) | ZNTL |  | completed | "Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516025000159/zntl_q32025earningspr.htm)) |
| November 10, 2025 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, November 10, 2025 (GlobeNewswire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312525273228/olma-ex99_1.htm)) |
| November 10, 2025 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm)) |
| November 10, 2025 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/avbp-20251110xex99d1.htm)) |
| November 10, 2025 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925112682/tm2531319d1_ex99-1.htm)) |
| November 10, 2025 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000119312525274314/prok-ex99_1.htm)) |
| November 10, 2025 | [Botox primary completion](https://sec-api.dev/pdufa/botox) | ABBV | Masseter Muscle Prominence | completed | "NCT06399718 (A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-10 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06399718)) |
| November 10, 2025 | [Clofazimine inhalation suspension primary completion](https://sec-api.dev/pdufa/clofazimine-inhalation-suspension) | MNKD |  | withdrawn | "NCT06418711 (ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-10 (ACTUAL); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06418711)) |
| November 10, 2025 | [LY3541860 primary completion](https://sec-api.dev/pdufa/ly3541860) | LLY | Rheumatoid Arthritis | withdrawn | "NCT06859294 (A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-11-10 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859294)) |
| November 11, 2025 | [CYPHERPUNK TECHNOLOGIES INC. earnings report](https://sec-api.dev/companies/cyph/catalysts) | CYPH |  | completed | "Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509745/000110465925109820/tm2530735d1_ex99-2.htm)) |
| November 11, 2025 | [Metagenomi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mgx/catalysts) | MGX |  | completed | "Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/mgx-ex99_1.htm)) |
| November 11, 2025 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Chronic Hepatitis B; Hepatitis B, Chronic | completed | "NCT05630807 (Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-11 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05630807)) |
| November 11, 2025 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 2 | completed | "NCT06555783 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-11 (ACTUAL); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06555783)) |
| November 12, 2025 | [Indaptus Therapeutics, Inc. earnings report](https://sec-api.dev/companies/indp/catalysts) | INDP |  | completed | "Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1857044/000149315225021758/ex99-1.htm)) |
| November 12, 2025 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312525275867/artv-ex99_1.htm)) |
| November 12, 2025 | [IBio, Inc. earnings report](https://sec-api.dev/companies/ibio/catalysts) | IBIO |  | completed | "Exhibit 99.1 iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420720/000142072025000039/ibio-20251112xex99d1.htm)) |
| November 12, 2025 | [Vireo Growth Inc. earnings report](https://sec-api.dev/companies/vreof/catalysts) | VREOF |  | completed | "Vireo Growth Inc. Announces Third Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771706/000110465925109800/vreof-20251112xex99d1.htm)) |
| November 12, 2025 | [Connect Biopharma Holdings Ltd earnings report](https://sec-api.dev/companies/cntb/catalysts) | CNTB |  | completed | "Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835268/000183526825000057/cntbq32025earningsrelease.htm)) |
| November 12, 2025 | [AN2 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/antx/catalysts) | ANTX |  | completed | "AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-ex99_1.htm)) |
| November 12, 2025 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/pmn-20251112xex99d1.htm)) |
| November 12, 2025 | [Neuropeptide topline data readout](https://sec-api.dev/pdufa/neuropeptide) | ALKS | narcolepsy type 2 | completed, positive | "DUBLIN, Nov. 12, 2025 -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312525276161/alks-ex99_1.htm)) |
| November 12, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. Reports third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025108716/ea026513601ex99-1_cormedix.htm)) |
| November 12, 2025 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- - Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ended September 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184325007222/exh_991.htm)) |
| November 12, 2025 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315225021721/ex99-1.htm)) |
| November 12, 2025 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000149315225021914/ex99-1.htm)) |
| November 12, 2025 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Announces Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm)) |
| November 12, 2025 | [Ovid Therapeutics Inc. earnings report](https://sec-api.dev/companies/ovid/catalysts) | OVID |  | completed | "Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/ovidexhibit9912025-q3.htm)) |
| November 12, 2025 | [NEONC TECHNOLOGIES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/nthi/catalysts) | NTHI |  | completed | "Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1979414/000182912625009221/neonctechnologies_ex99-1.htm)) |
| November 12, 2025 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312525275888/ck0001534133-ex99_1.htm)) |
| November 12, 2025 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Rockwell Medical Announces Third Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000162828025051267/a2025q3earningspr.htm)) |
| November 12, 2025 | [AUCATZYL (obecabtagene autoleucel) earnings report](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates November 12, 2025 at 7:00 AM EST Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/autlex-991pr121125.htm)) |
| November 12, 2025 | [Corbus Pharmaceuticals Holdings, Inc. earnings report](https://sec-api.dev/companies/crbp/catalysts) | CRBP |  | completed | "Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000119312525276062/crbp-ex99_1.htm)) |
| November 12, 2025 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112xexx991.htm)) |
| November 12, 2025 | [ATOSSA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atos/catalysts) | ATOS |  | completed | "Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000119312525276140/atos-ex99_1.htm)) |
| November 12, 2025 | [Prelude Therapeutics Inc earnings report](https://sec-api.dev/companies/prld/catalysts) | PRLD |  | completed | "Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1678660/000119312525275871/prld-ex99_1.htm)) |
| November 12, 2025 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465925110343/ganx-20251112xex99d1.htm)) |
| November 12, 2025 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports Third Quarter 2025 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000119312525277571/eras-ex99_1.htm)) |
| November 12, 2025 | [BeyondSpring Inc. earnings report](https://sec-api.dev/companies/bysi/catalysts) | BYSI |  | completed | "BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677940/000117184325007217/exh_991.htm)) |
| November 12, 2025 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925110344/tm2530914d1_ex99-1.htm)) |
| November 12, 2025 | [PepGen Inc. earnings report](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed | "PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835597/000119312525276019/pepg-ex99_1.htm)) |
| November 12, 2025 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000070/crbu-20251112xexx991.htm)) |
| November 12, 2025 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925109744/tm2530945d1_ex99-1.htm)) |
| November 12, 2025 | [ELITE PHARMACEUTICALS INC /NV/ FDA approval](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed, approved | "Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315225021717/ex99-1.htm)) |
| November 12, 2025 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/exhibit991-earningsrelease.htm)) |
| November 12, 2025 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000109/exhibit99-1earningspressre.htm)) |
| November 12, 2025 | [Atea Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/avir/catalysts) | AVIR |  | completed | "Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1593899/000119312525277627/d47505dex991.htm)) |
| November 12, 2025 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - November 12, 2025 — Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/aztrpressrelease09302025-e.htm)) |
| November 12, 2025 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000119312525277468/cue-ex99_1.htm)) |
| November 12, 2025 | [Lyell Immunopharma, Inc. earnings report](https://sec-api.dev/companies/lyel/catalysts) | LYEL |  | completed | "Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000162828025051603/lyel-20251112x8kexx991.htm)) |
| November 12, 2025 | [Coya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835022/000119312525276022/coya-ex99_1.htm)) |
| November 12, 2025 | [Silexion Therapeutics Corp earnings report](https://sec-api.dev/companies/slxn/catalysts) | SLXN |  | completed | "Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm)) |
| November 12, 2025 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125041544/ef20058670_ex99-1.htm)) |
| November 12, 2025 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025108847/ea026522701ex99-1_unicycive.htm)) |
| November 12, 2025 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, November 12, 2025 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operating results for the quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/exhibit991-2025q310xqpr.htm)) |
| November 12, 2025 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447dex991.htm)) |
| November 12, 2025 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465925110548/anvs-20251112xex99.htm)) |
| November 12, 2025 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774925034442/ex_886964.htm)) |
| November 12, 2025 | [Aprea Therapeutics, Inc. earnings report](https://sec-api.dev/companies/apre/catalysts) | APRE |  | completed | "Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781983/000110465925109860/apre-20251112xex99d1.htm)) |
| November 12, 2025 | [AUCATZYL (obecabtagene autoleucel) trial start](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Early-stage pipeline programs and collaborations In November 2025, Moderna announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, an investigational mRNA-based T-cell engager for participants with relapsed or refractory multiple myeloma. mRNA-2808 utilizes an Autolus proprietary binder that was licensed to Moderna in 2022." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/autlex-991pr121125.htm)) |
| November 12, 2025 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported financial results for the third quarter of 2025 and provided an update on its late-stage agitation clinical development programs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/tm2530979d1_ex99-1.htm)) |
| November 12, 2025 | [IRulya Therapeutics Inc. earnings report](https://sec-api.dev/companies/irla/catalysts) | IRLA |  | completed | "SOUTH SAN FRANCISCO, Calif. - November 12, 2025 - Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/qncx-ex99_1.htm)) |
| November 12, 2025 | [BridgeBio Oncology Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bbot/catalysts) | BBOT |  | completed | "BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1869105/000119312525277601/d814249dex991.htm)) |
| November 12, 2025 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925109737/tm2530850d1_ex99-1.htm)) |
| November 12, 2025 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED NOVEMBER 12, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea026541601ex99-1_therape.htm)) |
| November 12, 2025 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000119312525277580/elvn-ex99_1.htm)) |
| November 12, 2025 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000119312525277569/kytx-ex99_1.htm)) |
| November 12, 2025 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465925110351/armp-20251112xex99d1.htm)) |
| November 12, 2025 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000021/sls-202511128xkexhibit991.htm)) |
| November 12, 2025 | [Valion Bio, Inc. earnings report](https://sec-api.dev/companies/vbio/catalysts) | VBIO |  | completed | "Tivic Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787740/000143774925035208/ex_860071.htm)) |
| November 12, 2025 | [Theriva (theriva) earnings report](https://sec-api.dev/pdufa/theriva) | TOVX |  | completed | "Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925109821/tm2530928d1_ex99-1.htm)) |
| November 12, 2025 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312525277521/bolt-ex99_1.htm)) |
| November 12, 2025 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000119312525275889/tcrx-ex99_1.htm)) |
| November 12, 2025 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000165495425012921/tennx_ex991.htm)) |
| November 12, 2025 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575dex991.htm)) |
| November 12, 2025 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774925034467/ex_887318.htm)) |
| November 12, 2025 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000133/imrx-20251112xexx991.htm)) |
| November 12, 2025 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312525276000/pmvp-ex99_1.htm)) |
| November 12, 2025 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm)) |
| November 12, 2025 | [ImageneBio, Inc. earnings report](https://sec-api.dev/companies/ima/catalysts) | IMA |  | completed | "ImageneBio Reports Third Quarter 2025 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077dex991.htm)) |
| November 12, 2025 | [Reyvow (lasmiditan succinate) primary completion](https://sec-api.dev/pdufa/lasmiditan) | LLY | Migraine | withdrawn | "NCT04396236 (A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04396236)) |
| November 12, 2025 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Mesothelioma, Malignant | completed | "NCT05136677 (A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05136677)) |
| November 12, 2025 | [NBI-921352 primary completion](https://sec-api.dev/pdufa/nbi-921352) | NBIX | SCN8A Developmental and Epileptic Encephalopathy Syndrome | withdrawn | "NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05226780)) |
| November 12, 2025 | [PRAX-562 primary completion](https://sec-api.dev/pdufa/prax-562) | PRAX | SCN2A Encephalopathy; SCN8A Encephalopathy | completed | "NCT05818553 (A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05818553)) |
| November 12, 2025 | [ABBV-932 primary completion](https://sec-api.dev/pdufa/abbv-932) | ABBV | Bipolar I Disorder; Bipolar II Disorder | completed | "NCT06605599 (Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06605599)) |
| November 13, 2025 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/ex99-1.htm)) |
| November 13, 2025 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., November 13, 2025 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525280518/d44321dex991.htm)) |
| November 13, 2025 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, November 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000110465925110883/mgtx-20251113xex99d1.htm)) |
| November 13, 2025 | [Cingulate Inc. NDA/BLA acceptance](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "2025, Cingulate announced that the U.S. Food and Drug Administration (FDA) had accepted for review the New Drug Application (NDA) for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/ex99-1.htm)) |
| November 13, 2025 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos" or the "Company"), today announced its financial results for the three and nine months ended September 30, 2025, which can be found at the Financial Results section of the Company's website at https://ir.pelthos.com/financial-info/financial-results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000175392625001766/g085015_ex99-1.htm)) |
| November 13, 2025 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Calif., November 13, 2025 - Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended September 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-1.htm)) |
| November 13, 2025 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000103/ngne_3q25earningsreleasexf.htm)) |
| November 13, 2025 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925034846/ex_886716.htm)) |
| November 13, 2025 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Inc. Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316825008288/xenetic_ex9901.htm)) |
| November 13, 2025 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm)) |
| November 13, 2025 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm)) |
| November 13, 2025 | [AYTU BIOPHARMA, INC earnings report](https://sec-api.dev/companies/aytu/catalysts) | AYTU |  | completed | "Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1385818/000143774925034822/ex_864172.htm)) |
| November 13, 2025 | [Vistagen Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vtgn/catalysts) | VTGN |  | completed | "Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1411685/000162828025052077/vtgn-20251113xex991.htm)) |
| November 13, 2025 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, November 13, 2025 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925034618/ex_883774.htm)) |
| November 13, 2025 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312525280125/kod-ex99_1.htm)) |
| November 13, 2025 | [Turn Therapeutics Inc. earnings report](https://sec-api.dev/companies/ttrx/catalysts) | TTRX |  | completed | "Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today reported financial results for the third quarter ended September" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023016/000121390025109580/ea026541301ex99-1_turn.htm)) |
| November 13, 2025 | [INTEGRATED BIOPHARMA INC interim data readout](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | scheduled | "After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements at least through the period ending November 13, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1016504/000143774924034953/inbp20240930_10q.htm)) |
| November 13, 2025 | [PRECIGEN, INC. earnings report](https://sec-api.dev/companies/pgen/catalysts) | PGEN |  | completed | "Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced third quarter 2025 financial results and business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010325014683/dp237316_ex9901.htm)) |
| November 13, 2025 | [SENTI-202 earnings report](https://sec-api.dev/pdufa/senti-202) | SNTI |  | completed | "Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/ex991snti2025q325earningsr.htm)) |
| November 13, 2025 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces Second Quarter 2026 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm)) |
| November 13, 2025 | [Cartesian Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/rnac/catalysts) | RNAC | systemic lupus erythematosus | completed, positive | "FREDERICK, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced positive initial data from the ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic lupus erythematosus (SLE)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/pressrelease11132025.htm)) |
| November 13, 2025 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312525279091/fate-ex99_1.htm)) |
| November 13, 2025 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315225022118/ex99-1.htm)) |
| November 13, 2025 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925034903/ex_887958.htm)) |
| November 13, 2025 | [Xilio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/xlo/catalysts) | XLO |  | completed | "WALTHAM, Mass., November 13, 2025 -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000119312525278835/xlo-ex99_1.htm)) |
| November 13, 2025 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Third QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925034621/ex_855915.htm)) |
| November 13, 2025 | [Aardvark Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aard/catalysts) | AARD |  | completed | "Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000119312525280235/ck0001774857-ex99_1.htm)) |
| November 13, 2025 | [Instil Bio, Inc. earnings report](https://sec-api.dev/companies/til/catalysts) | TIL |  | completed | "Instil Bio Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm)) |
| November 13, 2025 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm)) |
| November 13, 2025 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm)) |
| November 13, 2025 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315225022277/ex99-1.htm)) |
| November 13, 2025 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000119312525278810/aura-ex99_1.htm)) |
| November 13, 2025 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925034829/ex_887249.htm)) |
| November 13, 2025 | [Q32 Bio Inc. earnings report](https://sec-api.dev/companies/qttb/catalysts) | QTTB |  | completed | "Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000119312525278805/qttb-ex99_1.htm)) |
| November 13, 2025 | [Jade Biosciences, Inc. earnings report](https://sec-api.dev/companies/jbio/catalysts) | JBIO |  | completed | "Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312525281498/d26766dex991.htm)) |
| November 13, 2025 | [Anebulo Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/aneb/catalysts) | ANEB |  | completed | "Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/ex99-1.htm)) |
| November 13, 2025 | [Cingulate Inc. earnings report](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "Inc. Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/ex99-1.htm)) |
| November 13, 2025 | [Century Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | completed | "('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465925110862/tm2530897d1_ex99-1.htm)) |
| November 13, 2025 | [RELMADA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/rlmd/catalysts) | RLMD |  | completed | "Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1553643/000121390025110088/ea026563001-8kex99i_relmada.htm)) |
| November 13, 2025 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312525280173/eq-ex99_1.htm)) |
| November 13, 2025 | [Lantern Pharma Inc. earnings report](https://sec-api.dev/companies/ltrn/catalysts) | LTRN |  | completed | "Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1763950/000149315225022134/ex99-1.htm)) |
| November 13, 2025 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the three and nine months ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/e664954_ex99-1.htm)) |
| November 13, 2025 | [Phio Pharmaceuticals Corp. earnings report](https://sec-api.dev/companies/phio/catalysts) | PHIO |  | completed | "Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000143774925034848/ex_865785.htm)) |
| November 13, 2025 | [Zura Bio Ltd earnings report](https://sec-api.dev/companies/zura/catalysts) | ZURA |  | completed | ""Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/tm2531128d1_ex99-1.htm)) |
| November 13, 2025 | [BioAtla, Inc. earnings report](https://sec-api.dev/companies/bcab/catalysts) | BCAB |  | completed | "BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826892/000119312525280141/bcab-ex99_1.htm)) |
| November 13, 2025 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports Financial Results for Third Quarter of 2025, Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm)) |
| November 13, 2025 | [Trevi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | completed | "Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1563880/000119312525280149/trvi-ex99_1.htm)) |
| November 13, 2025 | [Arbutus Biopharma Corp earnings report](https://sec-api.dev/companies/abus/catalysts) | ABUS |  | completed | "Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1447028/000117184325007256/exh_991.htm)) |
| November 13, 2025 | [Acrivon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrv/catalysts) | ACRV |  | completed | "Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781174/000119312525280172/acrv-ex99_1.htm)) |
| November 13, 2025 | [Oric Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/oric/catalysts) | ORIC |  | completed | "ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280196/oric-ex99_1.htm)) |
| November 13, 2025 | [PDS Biotechnology Corp earnings report](https://sec-api.dev/companies/pdsb/catalysts) | PDSB |  | completed | "PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036125041805/ef20058907_ex99-1.htm)) |
| November 13, 2025 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "Announces Third Quarter 2025 Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/tm2531079d1_ex99-1.htm)) |
| November 13, 2025 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates  In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as of November 6, 2025.  Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions and deaths may reflect a favorable impact on disease-free survival ("DFS")" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/elicioq325prdraft_111320.htm)) |
| November 13, 2025 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000170859925000135/ser-20251113xex991_earning.htm)) |
| November 13, 2025 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "-- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the quarter ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465925110848/tm2531151d1_ex99-1.htm)) |
| November 13, 2025 | [CV Sciences, Inc. earnings report](https://sec-api.dev/companies/cvsi/catalysts) | CVSI |  | completed | "CV Sciences, Inc. Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1510964/000119312525280116/cvsi-ex99_1.htm)) |
| November 13, 2025 | [Traws Pharma, Inc. earnings report](https://sec-api.dev/companies/traw/catalysts) | TRAW |  | completed | "Reports Third Quarter 2025 Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465925110829/tm2531045d1_ex99-1.htm)) |
| November 13, 2025 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, November 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465925110821/plx-20251113xex99d1.htm)) |
| November 13, 2025 | [Exagamglogene autotemcel primary completion](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn | completed | "NCT03655678 (A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03655678)) |
| November 13, 2025 | [MRNA-1010 primary completion](https://sec-api.dev/pdufa/mrna-1010) | MRNA | Influenza | completed | "NCT05606965 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05606965)) |
| November 13, 2025 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | IgG4 Related Disease | completed | "NCT05662241 (A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662241)) |
| November 13, 2025 | [Psilocybin primary completion](https://sec-api.dev/pdufa/psilocybin) | CMPS | Treatment Resistant Depression | completed | "NCT05711940 (Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05711940)) |
| November 13, 2025 | [KOMZIFTI (ziftomenib) FDA approval](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory | completed, approved | "Komzifti \| ziftomenib \| 11/13/2025 \| To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| November 14, 2025 | [Biologics earnings report](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed | "Miramar, FL - November 14, 2025 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, today reported financial results and recent business highlights for its three months ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000119312525283230/hcwb-ex99_1.htm)) |
| November 14, 2025 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525283078/d99039dex991.htm)) |
| November 14, 2025 | [GT Biopharma, Inc. earnings report](https://sec-api.dev/companies/gtbp/catalysts) | GTBP |  | completed | "Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/109657/000149315225022631/ex99-1.htm)) |
| November 14, 2025 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "Technologies Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm)) |
| November 14, 2025 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm)) |
| November 14, 2025 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | "November 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525283075/d93377dex991.htm)) |
| November 14, 2025 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Mass., November 14, 2025 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000149315225023441/ex99-1.htm)) |
| November 14, 2025 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "NEW YORK, NY — November 14, 2025 (Globe Newswire) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and immune disorders, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update highlighting durable clinical responses with agenT-797, expansion of its iNKT platform across oncology, inflammation and transplantation, and strengthening of its leadership team as the company advances toward pivotal development." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-ex99_1.htm)) |
| November 14, 2025 | [Marker Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mrkr/catalysts) | MRKR |  | completed | "Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/tm2530894d1_ex99-1.htm)) |
| November 14, 2025 | [ABP-450 earnings report](https://sec-api.dev/pdufa/abp-450) | AEON |  | completed | "AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm)) |
| November 14, 2025 | [TuHURA Biosciences, Inc./NV earnings report](https://sec-api.dev/companies/hura/catalysts) | HURA |  | completed | "TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000119312525281522/hura-ex99_1.htm)) |
| November 14, 2025 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585dex991.htm)) |
| November 14, 2025 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312525283294/eldn-ex99_1.htm)) |
| November 14, 2025 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315225023419/ex99-1.htm)) |
| November 14, 2025 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315225023629/ex99-1.htm)) |
| November 14, 2025 | [Azora Therapeutics, Inc. (DE) earnings report](https://sec-api.dev/companies/azr/catalysts) | AZR |  | completed | "Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1513525/000121390025110385/ea026541801ex99-1_adial.htm)) |
| November 14, 2025 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/ex99-1.htm)) |
| November 14, 2025 | [Benitec Biopharma Inc. earnings report](https://sec-api.dev/companies/bntc/catalysts) | BNTC |  | completed | "platform, today announced financial results for its first fiscal quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1808898/000119312525283351/d811784dex991.htm)) |
| November 14, 2025 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/ex99-1.htm)) |
| November 14, 2025 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/exhibit99109302025.htm)) |
| November 14, 2025 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036125042118/ny20058903x1_ex99-1.htm)) |
| November 14, 2025 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/ck0001991792-ex99_1.htm)) |
| November 14, 2025 | [Twist Bioscience Corp earnings report](https://sec-api.dev/companies/twst/catalysts) | TWST |  | completed | "Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581280/000158128025000020/twst-20250930xex991.htm)) |
| November 14, 2025 | [ZYCUBO (CUTX-101) NDA/BLA submission](https://sec-api.dev/pdufa/cutx-101) | FBIO |  | completed | "November 14, 2025, Sentynl notified Cyprium that Sentynl had resubmitted the NDA for CUTX-101 to the FDA." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465925112945/tm2531443d1_8k.htm)) |
| November 14, 2025 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/srrk-20251114xex99d1.htm)) |
| November 14, 2025 | [Entera Bio Ltd. earnings report](https://sec-api.dev/companies/entx/catalysts) | ENTX |  | completed | "Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638097/000117891325003851/exhibit_99-1.htm)) |
| November 14, 2025 | [Galcanezumab primary completion](https://sec-api.dev/pdufa/galcanezumab) | LLY | Episodic Migraine | completed | "NCT03432286 (A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03432286)) |
| November 14, 2025 | [Tolebrutinib primary completion](https://sec-api.dev/pdufa/tolebrutinib) | SNY | Primary Progressive Multiple Sclerosis | completed | "NCT04458051 (Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04458051)) |
| November 14, 2025 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight; Osteo Arthritis Knee | completed | "NCT05931367 (A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05931367)) |
| November 14, 2025 | [Menacyw conjugate vaccine primary completion](https://sec-api.dev/pdufa/menacyw-conjugate-vaccine) | SNY | Meningococcal Immunisation; Healthy Volunteers | completed | "NCT06284915 (Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company; Results First Posted 2026-10-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06284915)) |
| November 14, 2025 | [Ar-17043 ophthalmic solution primary completion](https://sec-api.dev/pdufa/ar-17043) | ALC | Open Angle Glaucoma; Ocular Hypertension | completed | "NCT06441643 (Next Generation Rocklatan): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Alcon Research." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06441643)) |
| November 15, 2025 | [Meningococcal polysaccharide (serogroups a, c, y, and w) tetanus toxoid conjugate vaccine primary completion](https://sec-api.dev/pdufa/meningococcal-polysaccharide-serogroups-a-c-y-and-w-tetanus-toxoid-conjugate-vac) | SNY | Meningococcal Immunisation; Healthy Volunteers | completed | "NCT05794230 (Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-15 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05794230)) |
| November 17, 2025 | [Ziihera® (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zanidatamab) | ZYME |  | completed, positive | "2025) - Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced positive topline results from the Phase 3" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000119312525283873/d17392dex991.htm)) |
| November 17, 2025 | [GEA-01 topline data readout](https://sec-api.dev/pdufa/gea-01) | JAZZ | HER2-positive locally advanced or metastatic GEA | completed, positive | "On November 17, 2025, we announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive ("HER2+") locally advanced or metastatic gastroesophageal adenocarcinoma ("GEA"), including cancers of the stomach, gastroesophageal junction, and esophagus." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm)) |
| November 17, 2025 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312525284633/enta-ex99_1.htm)) |
| November 17, 2025 | [ORAMED PHARMACEUTICALS INC. earnings report](https://sec-api.dev/companies/ormp/catalysts) | ORMP |  | completed | "Oramed Reports Fiscal Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1176309/000121390025111310/ea026594901ex99-1_oramed.htm)) |
| November 17, 2025 | [VERZENIO (abemaciclib) NDA/BLA submission](https://sec-api.dev/pdufa/abemaciclib) | ATOS |  | scheduled | "The Company expects to meet with the FDA on November 17, 2025, to discuss a development plan intended to support filing an NDA, including the potential use of expedited programs where eligible." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000119312525276140/atos-ex99_1.htm)) |
| November 17, 2025 | [Jazz Pharmaceuticals plc topline data readout](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed, positive | "November 17, 2025 — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060dex991.htm)) |
| November 17, 2025 | [TONMYA (tonmya) FDA approval](https://sec-api.dev/pdufa/tonmya) | TNXP |  | completed, approved | "TONMYA, Tonix's first internally developed product to become FDA approved, was commercially launched by the Company in the United States on November 17, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1430306/000199937126010486/tnxp-10q_033126.htm)) |
| November 17, 2025 | [MRNA-1083 primary completion](https://sec-api.dev/pdufa/mrna-1083) | MRNA | COVID-19; Influenza | completed | "NCT06694389 (Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-17 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06694389)) |
| November 17, 2025 | [EVO301 primary completion](https://sec-api.dev/pdufa/evo301) | EVMN | Atopic Dermatitis (AD); Eczema; Eczema Atopic Dermatitis | completed | "NCT06723405 (Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-17 (ACTUAL); Lead Sponsor Evommune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06723405)) |
| November 17, 2025 | [WEZLANA® (ustekinumab) primary completion](https://sec-api.dev/pdufa/ustekinumab) | JNJ | Plaque Psoriasis | completed | "NCT06934226 (A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-17 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06934226)) |
| November 18, 2025 | [FMXIN002 trial start](https://sec-api.dev/pdufa/ns002) | NSRX |  | completed | "Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2029039/000149315225023992/ex99-1.htm)) |
| November 18, 2025 | [HCW9302 trial start](https://sec-api.dev/pdufa/hcw9302) | HCWB | autoimmune disorder | completed | "On November 18, 2025, HCW Biologics Inc. (the "Company") issued a press release announcing that the first patient was dosed in a Company-sponsored, multi-center Phase 1 clinical trial to evaluate the Company's lead product candidate, HCW9302, in patients with an autoimmune disorder." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828673/000119312525285325/hcwb-20251117.htm)) |
| November 18, 2025 | [TEPKINLY (epcoritamab) FDA approval](https://sec-api.dev/pdufa/epcoritamab) | GMAB | relapsed or refractory | completed, approved | "COPENHAGEN, Denmark; November 18, 2025 - Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000095/gmab_20251118xex99d1.htm)) |
| November 18, 2025 | [CMND-100 topline data readout](https://sec-api.dev/pdufa/cmnd-100) | CMND | Alcohol Use Disorder | completed, positive | "Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced positive top-line results from the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390025112114/ea026618401ex99-1_clearmind.htm)) |
| November 18, 2025 | [REDEMPLO (plozasiran) PDUFA date](https://sec-api.dev/pdufa/plozasiran) | ARWR |  | completed, approved | "Arrowhead submitted a New Drug Application for approval of plozasiran in November 2024, and FDA has set a Prescription Drug User Fee Act ("PDUFA") action date of November 18, 2025—the target deadline by which FDA may make a decision on whether to approve plozasiran." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940725000007/a9912025-09x10arrowheadc.htm)) |
| November 18, 2025 | [Vyome Holdings, Inc earnings report](https://sec-api.dev/companies/hind/catalysts) | HIND |  | completed | "(NASDAQ: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and a series of corporate and clinical milestones following its successful listing on Nasdaq." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427570/000121390025112728/ea026634701ex99-1_vyome.htm)) |
| November 18, 2025 | [Epkinly (epcoritamab-bysp) label expansion decision](https://sec-api.dev/pdufa/epcoritamab-bysp) | GMAB |  | completed, approved | "BLA761324 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20251118, review_priority PRIORITY; sponsor_name GENMAB US, INC.; product EPKINLY (EPCORITAMAB-BYSP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761324%22)) |
| November 18, 2025 | [Tecentriq® (atezolizumab) primary completion](https://sec-api.dev/pdufa/atezolizumab) | NVCR | Metastatic Pancreatic Ductal Adenocarcinoma | completed | "NCT06390059 (EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-18 (ACTUAL); Lead Sponsor NovoCure Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06390059)) |
| November 18, 2025 | [Taltz (ixekizumab) primary completion](https://sec-api.dev/pdufa/ixekizumab) | LLY | Psoriatic Arthritis; Obesity | completed | "NCT06588296 (Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-18 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588296)) |
| November 18, 2025 | [REDEMPLO (plozasiran) FDA approval](https://sec-api.dev/pdufa/plozasiran) | ARWR | To reduce triglycerides in adults with familial chylomicronemia syndrome | completed, approved | "Redemplo \| plozasiran \| 11/18/2025 \| To reduce triglycerides in adults with familial chylomicronemia syndromeDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| November 19, 2025 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | completed, positive | "TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive interim results from its ongoing Phase 2 open-label STARBORN-1 trial assessing intracystic injection of TARA-002, the Company's investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/ea026638401ex99-2_protara.htm)) |
| November 19, 2025 | [PAVBLU® (aflibercept) label expansion decision](https://sec-api.dev/pdufa/aflibercept) | REGN |  | completed, approved | "BLA761355 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA HD (AFLIBERCEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761355%22)) |
| November 19, 2025 | [ABP-450 interim data readout](https://sec-api.dev/pdufa/abp-450) | AEON |  | scheduled | "- FDA Type 2a meeting scheduled for November 19, 2025 to review AEON's analytical development plan and initial data -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm)) |
| November 19, 2025 | [ProPhase Labs, Inc. earnings report](https://sec-api.dev/companies/prph/catalysts) | PRPH |  | completed | "Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/868278/000149315225024174/ex99-1.htm)) |
| November 19, 2025 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| November 19, 2025 | [IGALMI® (dexmedetomidine) label expansion decision](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed, approved | "NDA215390 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority STANDARD; sponsor_name BIOXCEL; product IGALMI (DEXMEDETOMIDINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215390%22)) |
| November 19, 2025 | [Erenumab dose 1 primary completion](https://sec-api.dev/pdufa/erenumab) | AMGN | Migraine | completed | "NCT03836040 (Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03836040)) |
| November 19, 2025 | [ABBV-916 primary completion](https://sec-api.dev/pdufa/abbv-916) | ABBV | Alzheimer's Disease (AD) | completed | "NCT05291234 (A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05291234)) |
| November 19, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes Mellitus | completed | "NCT06065540 (A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06065540)) |
| November 19, 2025 | [Koselugo (selumetinib sulfate) label expansion decision](https://sec-api.dev/pdufa/selumetinib) | AZN |  | completed, approved | "NDA213756 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority STANDARD; sponsor_name ASTRAZENECA; product KOSELUGO (SELUMETINIB SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213756%22)) |
| November 19, 2025 | [Imdelltra (tarlatamab-dlle) label expansion decision](https://sec-api.dev/pdufa/tarlatamab-dlle) | AMGN |  | completed, approved | "BLA761344 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority PRIORITY; sponsor_name AMGEN INC; product IMDELLTRA (TARLATAMAB-DLLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761344%22)) |
| November 20, 2025 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Plaque Psoriasis | completed | "NCT05565560 (A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05565560)) |
| November 20, 2025 | [Botox primary completion](https://sec-api.dev/pdufa/botox) | ABBV | Masseter Muscle Prominence | completed | "NCT06068855 (A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06068855)) |
| November 20, 2025 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | completed | "NCT06664801 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06664801)) |
| November 20, 2025 | [Retevmo (selpercatinib) label expansion decision](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20251120, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| November 21, 2025 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| November 21, 2025 | [Livtencity (maribavir) label expansion decision](https://sec-api.dev/pdufa/maribavir) | TAK |  | completed, approved | "NDA215596 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product LIVTENCITY (MARIBAVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215596%22)) |
| November 21, 2025 | [Alis primary completion](https://sec-api.dev/pdufa/alis) | INSM | Mycobacterium Infections, Nontuberculous | completed | "NCT04677569 (Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04677569)) |
| November 21, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Alcohol-related Liver Disease | completed | "NCT06409130 (Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06409130)) |
| November 21, 2025 | [Active imp primary completion](https://sec-api.dev/pdufa/active-imp) | AZN | Obesity or Overweight | completed | "NCT06579092 (Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579092)) |
| November 21, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | completed | "NCT06584916 (A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06584916)) |
| November 21, 2025 | [Qtorin 3.9% rapamycin anhydrous gel primary completion](https://sec-api.dev/pdufa/qtorin-3-9-rapamycin-gel) | PVLA | Cutaneous Venous Malformations | completed | "NCT06653842 (A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Palvella Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06653842)) |
| November 21, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-188 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| November 21, 2025 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| November 24, 2025 | [Onasemnogene abeparvovec FDA approval](https://sec-api.dev/pdufa/onasemnogene-abeparvovec) | NVS |  | completed, approved | "Basel, November 24, 2025 - Novartis today announced that the US Food and Drug Administration (FDA) has approved" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184325007547/f6k_112425.htm)) |
| November 24, 2025 | [Avt06 complete response letter (CRL)](https://sec-api.dev/pdufa/avt06) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761435_20251124.pdf%22)) |
| November 24, 2025 | [Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) label expansion decision](https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab) | BMY |  | completed, approved | "BLA761381 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20251124, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22)) |
| November 24, 2025 | [Nirsevimab primary completion](https://sec-api.dev/pdufa/nirsevimab) | AZN | Lower Respiratory Tract Infection | completed | "NCT05110261 (Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05110261)) |
| November 24, 2025 | [Yescarta (axicabtagene ciloleucel) primary completion](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) | GILD | Relapsed or Refractory Large B-cell Lymphoma | completed | "NCT05459571 (Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05459571)) |
| November 24, 2025 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension; Resistant Hypertension | completed | "NCT06344104 (A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06344104)) |
| November 24, 2025 | [Optic white adv sparkling white (2%hp) toothpaste primary completion](https://sec-api.dev/pdufa/optic-white-adv-sparkling-white-2-hp-toothpaste) | CL | Whitening | completed | "NCT07276672 (Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide in the Immediate Removal of Tooth Stains After a Single Brushing.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276672)) |
| November 25, 2025 | [Scemblix (asciminib) label expansion decision](https://sec-api.dev/pdufa/asciminib) | NVS |  | completed, approved | "NDA215358 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251125, review_priority STANDARD; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22)) |
| November 25, 2025 | [ARROWHEAD PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/arwr/catalysts) | ARWR |  | completed | "Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940725000027/arwr-202511258kex991.htm)) |
| November 25, 2025 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-52 (Efficacy): submission_status AP, submission_status_date 20251125, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| November 25, 2025 | [ANAVEX (anavex) earnings report](https://sec-api.dev/pdufa/anavex) | AVXL |  | completed | "Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its fourth quarter of fiscal 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1314052/000173112225001591/e7068_ex99-1.htm)) |
| November 25, 2025 | [Hmpl-523(300mg po qd) primary completion](https://sec-api.dev/pdufa/hmpl-523) | HCM | Warm Antibody Autoimmune Hemolytic Anemia | completed | "NCT05535933 (HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05535933)) |
| November 25, 2025 | [Pemvidutide primary completion](https://sec-api.dev/pdufa/pemvidutide) | ALT | Non-Alcoholic Steatohepatitis (NASH) | completed | "NCT05989711 (IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Altimmune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05989711)) |
| November 25, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06181435)) |
| November 25, 2025 | [Camzyos® (mavacamten) primary completion](https://sec-api.dev/pdufa/mavacamten) | BMY | Cardiomyopathy, Hypertrophic | completed | "NCT06253221 (A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06253221)) |
| November 25, 2025 | [Botox primary completion](https://sec-api.dev/pdufa/botox) | ABBV | Masseter Muscle Prominence | completed | "NCT06387394 (A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06387394)) |
| November 26, 2025 | [Avto5 complete response letter (CRL)](https://sec-api.dev/pdufa/avto5) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761461_20251126.pdf%22)) |
| November 26, 2025 | [BEQALZI™ (sonrotoclax) NDA/BLA acceptance](https://sec-api.dev/pdufa/sonrotoclax) | ONC |  | completed | "On November 26, 2025, we announced that the U.S. Food and Drug Administration ("FDA") accepted and granted Priority Review to a New Drug Application ("NDA") for sonrotoclax for the treatment of adult patients with R/R MCL, following treatment with a Bruton's tyrosine kinase ("BTK") inhibitor." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm)) |
| November 26, 2025 | [FILSPARI (sparsentan) topline data readout](https://sec-api.dev/pdufa/sparsentan) | LGND |  | completed, positive | "•On November 26, 2025, Renalys Pharma, Inc., now Chugai Pharmaceuticals, announced positive topline results from its Phase 3 clinical study of sparsentan, an orally administered dual endothelin and angiotensin II receptor antagonist, in Japanese patients with IgA nephropathy (IgAN)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm)) |
| November 26, 2025 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Alopecia Areata | completed | "NCT06340360 (A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-26 (ACTUAL); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340360)) |
| November 30, 2025 | [KOMZIFTI (ziftomenib) PDUFA date](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory NPM1-m AML | completed, approved | "Continued regulatory interactions with the FDA ahead of the November 30, 2025 PDUFA target action date for ziftomenib as a monotherapy for adult patients with relapsed or refractory NPM1-m AML." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-ex99_1.htm)) |
| November 30, 2025 | [TEPKINLY (epcoritamab) PDUFA date](https://sec-api.dev/pdufa/epcoritamab) | GMAB |  | completed, approved | "•U.S. FDA has accepted for priority review new supplemental Biologics License Application (sBLA) for epcoritamab plus R2, with action date of November 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000061/gmab_20250807xex99d1.htm)) |
| November 30, 2025 | [YUVIWEL® (navepegritide) PDUFA date](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | delayed | "TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525277532/d88973dex991.htm)) |
| November 30, 2025 | [KOMET-001 PDUFA date](https://sec-api.dev/pdufa/komet-001) | KURA |  | scheduled | "ZIFTOMENIB Targeted investigational menin inhibitor for relapsed/refractory and newly diagnosed acute myeloid leukemia (AML) New Drug Application (NDA) based on positive results from the Phase 2 KOMET-001 trial NDA granted Priority Review and assigned Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 Kyowa Kirin partnership funds expansive AML development program through 1L U.S. commercialization" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/d939526dex991.htm)) |
| November 2025 | [Bivalent enterovirus vaccine (vero cell), inactivated primary completion](https://sec-api.dev/pdufa/bivalent-enterovirus-vaccine-vero-cell-inactivated) | SVA | Hand, Foot, and Mouth Disease（HFMD) | delayed | "NCT06734832 (Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-11-30 (ESTIMATED); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06734832)) |

Other months: https://sec-api.dev/fda-calendar/2025-10 , https://sec-api.dev/fda-calendar/2025-12. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates November 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-11

```bibtex
@misc{secapidev_fda_calendar_2025_11_20261116,
  title        = {PDUFA dates November 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-11}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_11_20261116","title":"PDUFA dates November 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-11","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
